Glaukos, based in Aliso Viejo, California, specializes in innovative therapies for glaucoma and retinal diseases, employing 907 staff since its IPO on June 25, 2015. Their products include micro-invasive devices and dropless treatments to reduce intraocular pressure.
Glaukos (GKOS) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Glaukos's actual EPS was -$0.22, beating the estimate of -$0.35 per share, resulting in a 37.96% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
